Navigation Links
Daclizumab shows potential for new immunoregulatory approach to treating MS
Date:2/16/2010

active lesions, supports further study of daclizumab."

Multiple sclerosis, one of the most common neurological disorders, affects more than 400,000 people in the United States each year. Despite significant advances in MS therapy, many patients continue to experience disease activity. There is a need for additional MS therapies that offer new approaches to treating the disease.

Daclizumab is a humanized monoclonal antibody that binds to CD25, a high affinity receptor that is expressed at low levels on resting T cells, which are a type of immune cell, and at high levels on T cells that can become activated in response to autoimmune conditions such as MS.

"Daclizumab is believed to work by selectively targeting immune cells that play a key role in MS without depleting healthy immune cells and has the potential to provide a new approach to treating this chronic and debilitating disease," said Gilmore O'Neill, senior director, Experimental Neurology at Biogen Idec. "Daclizumab was well tolerated in the CHOICE trial and significantly reduced MS activity in patients who were not responding to interferon beta."

"We believe the results from the CHOICE study, combined with clinical data from smaller trials of daclizumab in MS, provide a basis for advancing daclizumab into registrational studies as a novel therapeutic for the treatment of patients with relapsing MS," said Mark Rolfe, Ph.D., senior vice president and chief scientific officer of Facet Biotech. "Despite advances in MS treatment, there remains a significant unmet medical need for new therapies such as daclizumab and we look forward to seeing data from our registrational studies."

Results from this Phase 2 study provided evidence for Biogen Idec and Facet Biotech to continue the development of daclizumab in two registrational trials in MS. The Phase 2b SELECT trial is evaluating the efficacy and safety of monthly subcutaneous daclizumab as a monotherapy versus place
'/>"/>

Contact: Kate Weiss
617-914-6524
GCI Health
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
2. Mescal worm test shows DNA leaks into preservative liquids
3. Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31%
4. Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy
5. UCBs Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
6. Tiny test tube experiment shows reaction of melting materials at the nano scale
7. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
8. Topical erectile dysfunction therapy shows promise
9. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
10. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
11. Video shows nanotube spins as it grows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 ... has announced the addition of Jain ... Technologies, Markets and Companies"  to their ... report describes and evaluates animal biotechnology ... and pharmaceuticals as well as improvement ...
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ... new report "Neuroprotection - Drugs, Markets and ... report describes the role of neuroprotection in acute ... nervous system as well as in chronic diseases ... underlying mechanisms of damage to neural tissues are ...
(Date:5/28/2015)... DryLet, LLC a biotechnology company ... as animal waste reduction, bioremediation, wastewater treatment, aquaculture ... treatment plants and restaurant kitchen settings, announced today ... June 3-5 in Des Moines, Iowa. , ManureMagicâ„¢ ... Street Journal article because of its industry-leading qualities ...
(Date:5/28/2015)... Biscayne Pharmaceuticals, Inc ., today announced ... hormone-releasing hormone (GHRH) technology will be discussed in a ... The data show that the family of receptors for ... present on many primary breast cancer cells regardless of ... could have broad anti-cancer potential in breast cancer. 1 ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... Incorporated,(Nasdaq: SPEX ) reported a net loss for the three months ended March 31,2008 ... on the company,s on-going Phase 3 clinical trial,in the use of Naturlose for the treatment ... million and reflected the,start-up costs for the trial., , ... ...
... Vista Partners announced today that,it has initiated coverage on ... of Research of Vista Partners stated, "Synvista is one ... across. The,company is conducting four Phase 2 trials in ... a $100M market, could begin to,produce revenues as early ...
... Phase 1c Study Demonstrates Dose-dependent Activity of Antidote ... Biosciences today announced,the Journal of Thrombosis and Haemostasis, ... and Haemostasis, has published the,Phase 1c clinical results ... two-component system comprised of an aptamer-based anticoagulant,RB006, and ...
Cached Biology Technology:Spherix Reports 1st Quarter Earnings 2Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI) 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 2Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 3Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis 4
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/10/2015)... -- Fingerprint Cards (FPC) has received an order ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... in China . The order value of ... + 1 000 MSEK for 2015.   Jörgen Lantto, ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... 20, 2011Spas that offer massage therapy using fragrant essential ... harmful indoor air pollutants such as volatile organic compounds ... Environmental Engineering Science , a peer-reviewed journal published ... is available free online at www.liebertpub.com/ees ...
... the association for informatics professionals, honors four leaders ... to be presented during AMIA,s Annual Symposium, Oct. ... professionals to the Washington Hilton over the coming ... whose contributions to the health sector have had ...
... HEIDELBERG, GERMANY, 20 OCTOBER 2011 EMBO today acknowledges ... 14 countries by awarding them life-long EMBO membership. ... to research excellence and the exceptional achievements made by ... ranks of 1,500 of the best researchers in Europe ...
Cached Biology News:Can aromatherapy produce harmful indoor air pollutants? 2AMIA honors informatics professionals who are improving health, changing the world 2AMIA honors informatics professionals who are improving health, changing the world 346 outstanding life scientists elected to EMBO membership 2
...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
Recombinant Mouse sTNF RII/TNFRSF1B...
Biology Products: